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Conclusion & Future Plan
▪ Compound 5 and 6, compare to other analougues showed most potent in
different cancer cell lines whereas, every analogues is non toxic to MCF-10.
▪ We will do further study in zebra fish animal model to investigate binding
target.
• We will also assay these two compounds in different mitochondrial targets.























































































Plasma concentration versus time profile▪ Amides with primary amine or aromatic amine are more potent in inhibiting 
the cancer cells growth  than with secondary amine or branched alkyl 
amine.
▪ Within each subset, the amines with a stronger electron withdrawing group 
exhibit better potency. 
▪ N-benzyl amides with an electron withdrawing group at the para position 
were the only compounds to inhibit the growth of triple-negative MDA-MB-
231 cells commensurate to olaparib.
▪ We will assay the anticancer activity of protected L-γ-Methyleneglutamine
analogues against MCF-7, SK-BR-3, MDA-MB-231 cell lines. 
▪ For most potent compound 5, we will do the PK/PD study.
▪ We will also investigate the anticancer activity of both metabolite and 
protected metabolites of L-γ-Methyleneglutamine analogues.
▪ For selected compounds from 1-10, we will study anticancer activity 
against brain, and head and neck cancer.
Protected L-γ-methyleneglutamate analogues & metabolites
Inhibition of cell growth Necrosis Study
PK study of compound 5
Inhibition of cell growth
Study on brain cancer Study on head and neck cancer
▪ Compare to compound 5 and 6, protected L-γ-methyleneglutamate
analogues, compound 11-30 did not show promising activity in MCF-7, SK-
BR-3, MDA-MB-231 cell lines.
▪ Both metabolites and protected metabolites, compound 31-35 also did not
show promising activity. However, compound 33 showed better activity in
MDA-MB-231 than others.
▪ PK study showed the good distribution of compound 5 in brain after 30
minutes.
▪ Study of compound 1,4-9 in brain, and head and neck cancer cell lines
showed the concentration dependent inhibition of cell growth of these
cancer cells.
▪ There are a number of naturally occurring glutamine analogues, such as 
azaserine, acivicin, and 6-diazo-5-oxo-L-norleucine (DON).
▪ These inhibit different glutamine- dependent enzymes including 
glutaminase, NAD synthase, CTP synthetase, FGAR aminotransferase.
▪ Therefore, they demonstrated variable degrees of gastrointestinal toxicity, 
myelosuppression, and neurotoxicity, due to their non-selectivity.
▪ L-γ-Methyleneglutamine (1) were first isolated from groundnut seedling 
(Arachis hypogaea) in 1952.
▪ It plays a major role in nitrogen transport in Arachis and Amorpha plants.
▪ The syntheses of racemic mixture of 1 were reported in 1955. However, no 
efficient synthetic route was reported before our work. 
▪ In cancer cells, glutaminolysis is the primary source of biosynthetic 
precursors, fueling the TCA cycle with glutamine-derived α-ketoglutarate.
▪ α-ketoglutarate provides carbons for the citric acid cycle to produce 
glutathione, fatty acids, and nucleotides. 
▪ It also contributes nitrogen to produce hexosamines, nucleotides, and many 
nonessential amino acids.
▪ Efforts to inhibit glutamine metabolism in cancer using amino acid analogs 
have been extensive.
